There are no major research houses that cover MELA. Firms that I know have coverage include:
Roth Capital - a bunch of Chinese stock pumpers Oppenheimer - great days were 20+ years ago WBB Securities - never heard of them BioLogic Equity Reasrch - never heard of them Brean Murray - small shop Boenning & Scattergood - small shop Needham - new $20 call...so far this was ignored, but Barron's press coverage should help bring attention to MELA and Needham's research. Leerink & Swan - had a $13-15 price target BEFORE approval.
Clearly, this is not a who's who of Wall Street...meaning there is nobody really covering MELA yet. Expect the firms listed above to issue new research reports and expect most of those to be upgrades to BUYS as several did not expect approval at all. And, expect new research coverage to be initiated shortly from new institutions. Both should provide multiple catalysts for additional buyers of MELA's stock.